Increased Serum Procollagen type I C-terminal Propeptide Levels are Associated with Left Ventricular Dysfunction in Patients Treated with Anthracycline-based Cancer Chemotherapy

Ana de la Fuente

Clinica Universidad de Navarra: Clinica Universidad de Navarra

Marta Santisteban

Clinica Universidad de Navarra Departamento de Oncología Médica: Clinica Universidad de Navarra Departamento de Oncología Médica

Josep Lupón

Hospital Universitari Germans Trias i Pujol

José Manuel Aramendía

Clinica Universidad de Navarra Departamento de Oncología Médica: Clinica Universidad de Navarra Departamento de Oncología Médica

Agnes Díaz

Clinica Universidad de Navarra

Germán Cediel

Hospital Universitari Germans Trias i Pujol

Begoña López

CIMA Universidad de Navarra

José María López Picazo

Clinica Universidad de Navarra Departamento de Oncología Médica: Clinica Universidad de Navarra Departamento de Oncología Médica

Gregorio Rábago

Clinica Universidad de Navarra

Javier Díez

Clinica Universidad de Navarra

Arantxa González

CIMA Universidad de Navarra

Antoni Bayés-Genís

Hospital Universitari Germans Trias i Pujol

Susana Ravassa (✉ sravassa@unav.es)

CIMA Universidad de Navarra <https://orcid.org/0000-0001-5926-5677>

Research

Keywords: Anthracycline-based chemotherapy, myocardial fibrosis, biomarkers, cardiotoxicity, global longitudinal strain, left ventricular ejection fraction

Posted Date: December 22nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-131637/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background Anthracycline-based cancer chemotherapy (ACC) has been related to myocardial interstitial fibrosis (MIF), a lesion contributing to left ventricular dysfunction (LVD). We investigated whether biomarker-assessed MIF was associated with LVD in patients with breast cancer receiving ACC and in patients with ACC-induced heart failure (ACC-HF). Moreover, chemotherapy agent's pro-fibrotic activity was evaluated in human cardiac fibroblasts (HCFs).

Methods Echocardiography, serum biomarkers of collagen deposition (procollagen type-I C-terminal-propeptide [PICP]) and crosslinking (collagen type-I C-terminal-telopeptide/matrix metalloproteinase-1 ratio), and biomarkers of myocardial and vascular stress (galectin-3, sST2, amino-terminal pro-brain natriuretic peptide [NT-proBNP], hs-troponin-T and vascular cell adhesion molecule-1 [VCAM-1]) were assessed in 70 breast cancer patients at baseline, and during ACC at 3 and 6 months. Subclinical cardiotoxicity was defined as a global longitudinal strain (GLS) relative reduction >15%. In addition, PICP and NT-proBNP were determined in 347 patients with different HF etiologies, 37 with ACC-HF of whom 33 had 12-month-follow-up LVEF assessment. HCF activation was examined after incubation with chemotherapy agents for 24 hours.

Results In breast cancer patients, six-months-ACC reduced GLS and upregulated PICP, hs-troponin-T, NT-proBNP and VCAM-1 ($P < 0.01$) versus baseline. At 6 months, elevation of PICP was higher in patients with subclinical cardiotoxicity versus the remaining patients (P for interaction < 0.001). PICP levels were directly associated with a relative reduction in GLS ($P < 0.001$). In ACC-HF patients, baseline LVEF was inversely associated with PICP and NT-proBNP ($P < 0.01$). After 12 months, LVEF did not change in patients with higher basal PICP (3rd tertile) but improved in the remaining patients ($P < 0.001$). Doxorubicin, cyclophosphamide and trastuzumab stimulated collagen synthesis in HCFs, including PICP extracellular cleavage.

Conclusion These results indicate that increased levels of PICP, a biomarker related to MIF, are associated with early LVD in ACC-treated patients with breast cancer and with established LVD in ACC-HF patients, hindering LV functional improvement after 12 months. Chemotherapy can directly activate collagen metabolism and increase PICP extracellular presence in HCFs. Therefore, PICP emerges as a promising biomarker of ACC-induced cardiotoxicity.

Background

Highly-effective oncologic drugs have led to important improvements in survival rates in patients with breast cancer. However, these agents are associated with side effects, cardiotoxicity among them, which limits treatment options and contributes to morbidity and mortality in these patients.^{1–4} Therefore, there is a critical need to understand the pathophysiological mechanisms taking place in the myocardium of patients undergoing cancer chemotherapy before irreversible cardiac damage occurs.⁵

Traditionally, cardiotoxicity due to breast cancer treatment, particularly anthracycline-based cancer chemotherapy (ACC), has been attributed to cardiomyocyte damage and death, with amino-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponins (hs-Tn) as the most commonly used biomarkers to detect cardiac damage in these patients.^{5,6} However, it has been suggested that myocardial interstitial fibrosis (MIF) is an additional important mechanism contributing to left ventricular dysfunction (LVD) and adverse clinical evolution in ACC-treated patients,^{6,7} as well as in patients treated with other oncologic drugs such as cyclophosphamide, taxane agents and anti-HER2 therapies.^{8–14} As cumulative evidence suggest that the detrimental impact of MIF on LV function is related to both an excess in collagen type-I fiber cross-linking and deposition,¹⁵ these characteristics of the collagen fiber should be evaluated in the myocardium of patients receiving ACC. In this regard, some circulating peptides with histologically-

proven association with MIF have been described. On the one hand, the serum procollagen type-I C-terminal propeptide (PICP), released during the conversion of procollagen type-I into fibril-forming mature collagen type-I, is directly correlated with LV myocardial collagen type-I deposition.¹⁶ On the other hand, the ratio of serum collagen type-I C-terminal telopeptide to serum matrix metalloproteinase-1 (CITP:MMP-1) is inversely correlated with LV myocardial collagen type-I cross-linking, as the higher is the cross-linking among collagen type-I fibrils, the lower will be the cleavage of CITP by MMP-1 during the process of fiber degradation.¹⁷

Therefore, we propose to investigate whether ACC induces biomarker-assessed MIF and whether this lesion is associated with early LVD in patients with breast cancer undergoing chemotherapy and with established LVD in patients with ACC-induced heart failure (ACC-HF). To address these questions, we have analyzed 3- and 6-month changes in the levels of serum PICP and CITP:MMP-1, and of other biomarkers associated with myocardial remodeling (e.g., vascular cell adhesion molecule-1 [VCAM-1], galectin-3 and soluble ST2 [sST2]) and injury-dysfunction (e.g., NT-proBNP and hs-TnT), in breast cancer patients undergoing ACC. In addition, we have evaluated biomarkers of MIF and injury-dysfunction in patients with ACC-HF in whom LV function has been re-assessed after 12 months follow-up. Finally, to characterize the pro-fibrotic mechanisms of breast cancer chemotherapy drugs, we have performed *in vitro* studies to analyze several aspects related to collagen metabolism in human cardiac fibroblasts (HCFs) incubated with these compounds.

Methods

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Investigation Ethics Committees of the University of Navarra and of the Hospital Universitari Germans Trias i Pujol. The study conformed to the principles of the Helsinki Declaration of 1975, as revised in 1983.

Study 1: Patients with breast cancer

Samples from patients included in the study were provided by the Biobank of the University of Navarra and were processed following standard operating procedures approved by the Clinical Investigation Ethics Committee of the University of Navarra.

Study population

Eighty-one patients with treatment-naïve primary breast cancer were prospectively recruited from 2017 to 2019 in the Breast Cancer Unit at the department of Medical Oncology at the University of Navarra Clinic. A total of 70 patients with planned treatment with epirubicin/cyclophosphamide and taxanes were eligible for inclusion (mean age 50.8 years, range 32–81 years). Reasons for exclusion included loss to follow-up (n = 7), incomplete baseline and follow-up data (n = 2) and unwillingness or inability to provide informed consent (n = 2). Epirubicin cumulative dose was < 300 mg/m² in 18 patients and 300–400 mg/m² in 52 patients. Twenty-three patients underwent surgery before chemotherapy and received adjuvant chemotherapy. The remaining patients received neoadjuvant chemotherapy before surgery procedure. Eighteen patients with HER2 overexpressing breast cancer received, in addition, targeted therapy (trastuzumab ± pertuzumab) administered concomitantly with taxanes. No patient had history of congenital heart disease, coronary heart disease, heart valve disease, heart failure or left ventricular ejection fraction (LVEF) < 50%.

Study protocol

Participants were studied before chemotherapy (baseline) and at standardized intervals after epirubicin/cyclophosphamide treatment at 3 months (visit 1) and after taxane treatment, with or without anti-HER2 therapy, at 6 months (visit 2). Transthoracic echocardiography, biochemical analyses and circulating biomarker determinations were performed at baseline, visit 1 and visit 2 (Fig. 1A). Two dimensional echocardiographic, pulsed Doppler, tissue Doppler imaging and three dimensional echocardiographic studies were performed in all patients using a Philips Epic 7 echocardiography system with a X5-1 transducer. The echocardiography studies' data were stored digitally in the Dicom server. End diastolic mid LV diameter, interventricular septal thickness and LV posterior wall thickness were measured as linear measurements with mode M. LV hypertrophy was diagnosed when the LV mass index (LVMI) was $> 115 \text{ g/m}^2$ for men and $> 95 \text{ g/m}^2$ for women.¹⁸ LVEF was measured using the biplane Simpson's method. LV longitudinal myocardial strain and Automated Function Imaging were assessed by an experienced investigator using the Automated Cardiac Motion Quantification (aCMQ) on Q-Lab software installed. For the Speckle-tracking analysis the software automatically traced the myocardial motion on the previously acquired images of four chamber, two chamber and three chamber standard apical views. The operator adjusted manually the myocardial limits if automated tracking was considered inaccurate. Global longitudinal strain (GLS) was obtained from an average of regional longitudinal strain measured from a 17 myocardial segments model.¹⁹ All measurements were made by a single observer who was blinded to all clinical and biomarker data. The intraobserver coefficients of variation for GLS and LVEF were 3.1% and 4.4%, respectively.

Early subclinical cardiotoxicity was defined as a relative decrease in 2D global longitudinal strain (GLS, as assessed by speckle-tracking analysis) $> 15\%$ versus baseline,²⁰ and established cardiotoxicity as an asymptomatic decrease in LVEF $> 15\%$ or an asymptomatic decrease of LVEF $> 10\%$ to an absolute value $< 53\%$ versus baseline.^{20,21}

Study 2: Patients with HF

Study population

The source of the study population from which this cohort is derived has been described elsewhere.²² In summary, all patients were ambulatory HF patients treated at a multidisciplinary unit from the Division of Cardiology at the Hospital Universitari Germans Trias i Pujol (Badalona, Spain). The principal referral criterion was HF according to the European Society of Cardiology guidelines irrespective of etiology, at least one HF hospitalization, and/or reduced LVEF. The present cohort inclusion criteria were baseline echocardiogram and biomarker measurement.

Three hundred and forty-seven HF patients at baseline were categorized according to etiologies as follows: 65 patients with ischemic heart disease (IHD), 85 with diabetic cardiomyopathy (DCM), 47 with hypertensive heart disease (HHD), 45 with valvular heart disease (VHD), 68 classified as "Others" which included alcoholic, hypertrophic and non-compacted cardiomyopathies and 37 with ACC-HF of whom twenty-four (64.9%) had been diagnosed with breast cancer. In these patients, anthracyclines (median [IQR] cumulative doses for epirubicine and doxorubicine: 540 [450–630] and 300 [278–413] mg/m², respectively) were given a median (IQR) of 7.0 (1.7–12.6) years ago, and the presence of cardiovascular comorbidities was further examined to exclude causes other than ACC therapy as the main driver of symptomatic HF.

Circulating Biomarkers

Blood samples were taken from the antecubital vein at the time of entry in the study, kept in ice for 1–2 hours maximum before processing, aliquoted and kept at -80°C until measurements. All biomarkers were measured in serum. NT-proBNP was measured using an ELISA (Roche Diagnostics). The inter-assay and intra-assay coefficients of variation were less than 10%. The lower limit of detection was 5 pg of NT-proBNP per mL. Hs-TnT was measured using

a highly sensitive assay (Troponin T hs STAT, Roche Diagnostics). The lower detection limit of the assay was 3 ng/l and the inter-assay coefficient less than 10%. Galectin-3 was measured by ELISA (BG Medicine). The inter-assay and intra-assay coefficients of variations were 8.0% y 4.4%, respectively. The lower limit of detection was 1.32 ng/mL. VCAM-1 was measured by using an alphaLISA (Perkin Elmer). The inter-assay and intra-assay coefficients of variation were 7.7% and 5.3%, respectively. The lower limit of detection was 0.92 pg/ml. Soluble ST2 was measured by using an EIA (ST2 Presage®, Critical Diagnostics). The inter-assay and intra-assay coefficients of variation were 6.6% and 6.1%, respectively. The lower limit of detection was 1.8 ng/ml. CITP was measured by radio-immuno assay (Orion Diagnostica). The inter-assay and intra-assay coefficients of variation were 10.2% and 9.3%, respectively. The lower limit of detection was 0.6 µg/L. MMP-1 was measured by an alphaLISA (PerkinElmer). The inter-assay and intra-assay coefficients of variation were 10.7% and 1.6%, respectively. The lower limit of detection was 82.6 pg/mL. CITP and MMP-1 values were expressed in molarity and their ratio was calculated in each patient as previously reported.¹⁷ PICP was measured using the EIA MicroVue CICP (Quidel Corporation). The inter-assay and intra-assay coefficients of variation were 9.1% and 4.1%, respectively. The lower limit of detection was 0.2 ng/mL.

Study 3: In vitro experiments

Cell Culture

Adult human dermal fibroblasts (HDF, Thermo Fisher Scientific) were grown in DMEM medium supplemented with 10% fetal bovine serum and fibroblast growth factor. Cells were left to expand until they reached 60% confluency and then starved in free-serum medium for 24 h. Dose-response curves in HDFs incubated with vehicle or chemotherapy agents for 24 h, including concentrations similar to those found in the blood of patients with breast cancer,^{23–25} were performed. Doxorubicin (Sigma-Aldrich) was tested at 5, 50, 250, 500 and 1000 nM, cyclophosphamide (BioVision) at 5, 10, 50, 100 and 250 µg/mL, and paclitaxel (Abcam) at 1, 2.5, 5, 10, 25, 50 µg/mL. Trastuzumab (BioVision) was tested at doses below those found in the plasma of patients with breast cancer treated with this antibody (0.01, 0.05, 0.1, 0.5, 1 and 2 µg/mL).^{26,27} HDF viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.

Primary cell cultures of HCFs were isolated from atrial samples obtained as discarded surgical tissue by mechanical and tissue enzymatic digestion with collagenases and characterized (i.e. vimentin staining) as previously described.²⁸ In addition, all cell cultures were tested for fibrotic response (increased mRNA procollagen type I expression) to the transforming growth factor-beta 1. All patients gave written informed consent to donate the tissue, and the Institutional Review Committee approved the study protocol. The study conformed to the principles of the Helsinki Declaration. Cells were left to expand until they reached 60% confluence. Cells were then starved in reduced serum medium for 24 h prior to stimulation with chemotherapy agents for another 24 h. The number of viable cells were determined upon trypan blue staining and counted in a Neubauer chamber.

Quantitative-Real-time PCR

mRNA levels were analysed in cell lysates by real-time quantitative PCR. Reverse transcription was performed with approximately 600 ng of total RNA by using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR was performed with a StepOne Plus Fast Real-time PCR system according to the manufacturer's recommendations (Applied Biosystems) by using specific qPCR assays (Integrated DNA Technologies, IDT) for alpha-smooth muscle actin [SMA] (Hs.PT.56a.20825574), procollagen type I (Hs.PT.58.15517795), procollagen type III (Hs.PT.58.40254063), procollagen C-proteinase [PCP] (Hs.PT.56a.25570664) and its enhancer [PCPE] (Hs.PT.58.40198057) and human lysyl oxidase [LOX] (Hs.PT.58.40011520). A specific qPCR assay for human

constitutive 18S ribosomal RNA (Hs.PT.39a.222148556.g) was used as endogenous control (IDT). Data were corrected by 18S ribosomal RNA and expressed as fold change versus unstimulated cells in arbitrary units.

Extracellular collagen content

Collagen content in the supernatants of HCFs was estimated by quantification of hydroxyproline in accordance with the instructions for the QuickZyme Total Collagen Assay (QuickZyme Biosciences). Data were normalized to viable cell number and expressed as fold change versus unstimulated cells.

Extracellular PICP content

PICP in the supernatants of HCFs was quantified using the alphaLISA PIP (PerkinElmer). The inter-assay and intra-assay coefficients of variation were < 1%. The lower limit of detection was 12 pg/mL. Data were normalized by viable cell number and expressed as fold change versus unstimulated cells.

LOX activity

LOX activity in the supernatants of HCFs was measured with a commercially available fluorimetric assay (AAT Bioquest) following the manufacturer's indications as previously described.²⁹ Data were normalized by viable cell number and expressed as fold change versus unstimulated cells.

Statistical analysis

Non-normally distributed variables were examined after logarithmic transformation. Differences between two groups of subjects were tested by Student's t test for unpaired data once normality was demonstrated. Otherwise, a nonparametric test (Mann-Whitney U test) was used. Differences among three groups or more were tested by one-way ANOVA followed by Bonferroni's post-hoc comparisons tests in case normality was demonstrated. Otherwise, a Kruskal-Wallis test was performed followed by Mann-Whitney U test with Bonferroni correction. Categorical variables were analyzed by the chi-squared test or Fisher's exact test when necessary. Baseline associations were examined by linear regression. Mixed-effects regression modelling was used for longitudinal and association analyses. Individual linear mixed-effects models with a random intercept to account for intraparticipant correlation of repeated measures were used to estimate changes across visits. In patients with breast cancer, subclinical cardiotoxicity at visit 2, visit, their interaction term, and baseline values of the dependent variable were added as fixed effects to examine whether the development of subclinical cardiotoxicity was accompanied by greater changes in the parameters of interest as compared with its absence over time. Visit as random slope was allowed if the model was significantly better fitted compared to a model with only random intercept. The variance component structure was specified according to the best fit model. The likelihood ratio test and Akaike information criterion were used to select the model with the best fit. To examine the independent association between PICP and GLS, confounding variables with P values < .10 in univariate analyses, including baseline GLS values, were considered in the multivariable analysis. Multicollinearity was defined as variance inflation factor (VIF) > 5 with model reduction in case any variable showed evidence of multicollinearity. The heteroscedasticity and normality of the residuals were examined by scatterplots and by the Skewness/Kurtosis test, respectively. Logistic regression analyses were used to assess the relationships of the biomarker levels at baseline, or biomarker changes versus baseline or between visits, with the presence of subclinical cardiotoxicity. Optimal cut-off values for predicting the development of subclinical cardiotoxicity at visit 2 were determined by performing receiver-operating characteristic (ROC) curve analysis followed by the calculation of the Youden's J statistic. The Benjamini and Hochberg multiple test correction (false discovery rate of 5%) was applied to all biomarker analyses.

Mixed-effect analyses were performed with the “mixed” command within STATA. Values are expressed as mean ± SD or median (interquartile range), and categorical variables as numbers and percentages. Statistical significance was set as a 2-sided P of 0.05. The statistical analyses were performed by using SPSS (15.0 version) and STATA (13.0 version) software.

Results

Study 1: Patients with breast cancer

Characteristics of patients at baseline

Table 1 shows the clinical characteristics of all patients at baseline. At the time of enrollment, 13 (18.6%) patients had hypertension, 9 (12.9%) were obese, 1 (1.4%) had diabetes, 5 (7.1%) smoked, 2 (2.9%) had eGFR values < 60 mL/min/1.73 m², and 1 (1.4%) had atrial fibrillation.

Table 1

Baseline clinical characteristics of all patients with breast cancer and of patients categorized according to the absence or presence of subclinical cardiotoxicity at visit 2

	All Patients	Subclinical cardiotoxicity		<i>P value</i>
	(n = 70)	No (n = 56)	Yes (n = 14)	
Age, years (min-max)	50.8 ± 12.4 (32–81)	50.8 ± 12.4	50.8 ± 13.1	0.99
BMI, kg/m ²	24.3 ± 4.5	24.3 ± 4.6	24.4 ± 4.8	0.98
Oncologic parameters, n (%)				
Breast cancer side				
Left	37 (52.9)	28 (50.0)	9 (64.3)	0.59
Right	32 (45.7)	27 (48.2)	5 (35.7)	
Bilateral	1 (1.4)	1 (1.8)	0 (0.0)	
Ki67, %	41.3 ± 25.1	42.1 ± 26.4	38.1 ± 19.4	0.54
ER and/or PR positive, n (%)	18 (25.7)	13 (23.2)	5 (35.7)	0.34
HER2 positive, n (%)	18 (25.7)	15 (26.8)	3 (21.4)	0.68
TNM Stage, n (%)				
I	11 (15.7)	10 (19.9)	1 (7.1)	0.13
IIA	23 (32.9)	16 (28.6)	7 (50.0)	
IIB	11 (15.7)	7 (12.5)	4 (28.6)	
IIIA	10 (14.3)	10 (17.9)	0 (0.0)	
IIIB	2 (2.9)	1 (1.8)	1 (7.1)	
IIIC	8 (11.4)	8 (14.3)	0 (0.0)	
IV	5 (7.1)	4 (7.1)	1 (7.1)	
Histology, n (%)				
Invasive Ductal	64 (91.4)	51 (91.1)	13 (92.9)	0.83
Other subtypes	6 (8.6)	5 (8.9)	1 (7.1)	
≥Median cumulative dose, n(%)				

BMI means body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; LVMI, left ventricular (LV) mass index; LVH, LV hypertrophy; RWT, relative wall thickness; LVEDVi, LV end-diastolic volume index; E, maximum early transmitral flow velocity in diastole; A, maximum late transmitral flow velocity in diastole; DT, deceleration time; LAVI, left atrial volume index; e', maximum early diastolic velocity of the mitral annulus displacement; LVESVi, LV end-systolic volume index; LVEF, LV ejection fraction; NT-proBNP, amino-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; sST2, soluble suppression of tumourigenicity-2; VCAM-1, vascular cell adhesion molecule-1; PICP, procollagen type I C-terminal propeptide; C1TP, collagen type I C-terminal telopeptide; MMP-1, matrix metalloproteinase-1. Quantitative variables are expressed as mean ± SD or median (interquartile range) and categorical variables as number (percentage).

	All Patients (n = 70)	Subclinical cardiotoxicity		<i>P value</i>
		No (n = 56)	Yes (n = 14)	
Epirubicin ≥ 377 mg/m ²	35 (50.0)	30 (53.6)	5 (35.7)	0.23
Cyclophosphamide ≥ 3820 mg/m ²	35 (50.0)	28 (50.0)	7 (50.0)	> 0.99
Taxanes, n(%)				
Paclitaxel	13 (18.6)	11 (19.6)	2 (14.3)	0.65
Docetaxel	57 (81.4)	45 (80.4)	12 (85.7)	
Other treatments, n(%)				
Carboplatin	19 (27.1)	16 (28.6)	3 (21.4)	0.59
Anti-HER2				
Trastuzumab	8 (11.4)	7 (12.5)	1 (7.1)	0.85
Trastuzumab + Pertuzumab	10 (14.3)	8 (14.3)	2 (14.3)	
Surgery, n (%)	23 (32.9)	21 (37.5)	2 (14.3)	0.10
Radiotherapy, n(%)	10 (14.3)	9 (16.1)	1 (7.1)	0.39
Cardiovascular comorbidities, n (%)				
Hypertension	13 (18.6)	10 (17.9)	3 (21.4)	0.76
Obesity	9 (12.9)	7 (12.5)	2 (14.3)	0.86
Dyslipemia	13 (18.6)	10 (17.9)	3 (21.4)	0.76
Diabetes Mellitus	1 (1.4)	0 (0.0)	1 (7.1)	
Current smoking	5 (7.1)	4 (7.1)	1 (7.1)	0.99
eGFR < 60 mL/min/1.73 m ²	2 (2.9)	2 (3.6)	0 (0.0)	
Atrial Fibrillation	1 (1.4)	1 (1.8)	0 (0.0)	
Cardiovascular treatments, n(%)				
ACE inhibitor	4 (5.7)	3 (5.4)	1 (7.1)	0.80
Angiotensin Receptor Blockers	5 (7.1)	3 (5.4)	2 (14.3)	0.26
Beta-blocker	2 (2.9)	1 (1.8)	1 (7.1)	0.36
BMI means body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; LVMI, left ventricular (LV) mass index; LVH, LV hypertrophy; RWT, relative wall thickness; LVEDVi, LV end-diastolic volume index; E, maximum early transmitral flow velocity in diastole; A, maximum late transmitral flow velocity in diastole; DT, deceleration time; LAVI, left atrial volume index; e', maximum early diastolic velocity of the mitral annulus displacement; LVESVi, LV end-systolic volume index; LVEF, LV ejection fraction; NT-proBNP, amino-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; sST2, soluble suppression of tumourigenicity-2; VCAM-1, vascular cell adhesion molecule-1; PICP, procollagen type I C-terminal propeptide; CITP, collagen type I C-terminal telopeptide; MMP-1, matrix metalloproteinase-1. Quantitative variables are expressed as mean $\pm$ SD or median (interquartile range) and categorical variables as number (percentage).				

	All Patients (n = 70)	Subclinical cardiotoxicity		<i>P value</i>
		No (n = 56)	Yes (n = 14)	
Diuretics	1 (1.4)	0 (0.0)	1 (7.1)	
Lipid-lowering drugs	8 (11.4)	7 (12.7)	1 (7.1)	0.56
Antiplatelet drugs	1 (1.4)	0 (0.0)	1 (7.1)	
Biochemical parameters				
Hematological				
Hemoglobin, g/dL	13.6 ± 1.0	13.4 ± 1.0	14.1 ± 0.7	0.038
Hematocrit, %	41.3 ± 3.0	40.9 ± 3.1	42.7 ± 2.2	0.048
Platelets, 10 ⁹ /L	274 ± 73.2	272 (241–305)	254 (213–285)	0.16
Leukocytes, 10 ⁹ /mL	6.5 (5.4–8.1)	6.5 (5.3–8.2)	6.6(5.7–8.1)	0.61
Neutrophils, %	61.0 ± 9.7	61.0 ± 10.3	61.2 ± 6.8	0.93
Lymphocytes, %	29.3 ± 8.4	29.6 ± 8.8	27.9 ± 6.5	0.50
Monocytes, %	7.3 ± 2.0	7.2 ± 2.1	7.6 ± 1.8	0.54
Renal function				
eGFR, mL/min/1.73 m ²	94.8 ± 17.0	94.3 ± 17.4	96.6 ± 15.4	0.66
Liver function				
AST, IU/L	18.0 (14.0–20.0)	18.0 (14.3–21.0)	15.0 (12.5–18.0)	0.05
ALT, IU/L	13.0 (11.0–17.0)	13.0 (11.8–18.3)	12.0 (9.0–16.5)	0.25
GGT, IU/L	17.5 (12.0–28.0)	18.0 (12.3–31.5)	14.5 (11.5–19.3)	0.30
ALP, IU/L	63.0 ± 22.9	64.8 ± 24.5	55.9 ± 13.2	0.19
Echocardiographic parameters				
2D Echocardiography and M mode				
LVMI, g/m ²	64.5 ± 14.1	63.3 ± 13.4	68.8 ± 16.2	0.20
LVH (LVMI > 95 g/m ²), n (%)	2 (2.9)	1 (1.8)	1 (7.1)	0.38

BMI means body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; LVMI, left ventricular (LV) mass index; LVH, LV hypertrophy; RWT, relative wall thickness; LVEDVi, LV end-diastolic volume index; E, maximum early transmitral flow velocity in diastole; A, maximum late transmitral flow velocity in diastole; DT, deceleration time; LAVI, left atrial volume index; e', maximum early diastolic velocity of the mitral annulus displacement; LVESVi, LV end-systolic volume index; LVEF, LV ejection fraction; NT-proBNP, amino-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; sST2, soluble suppression of tumourigenicity-2; VCAM-1, vascular cell adhesion molecule-1; PICP, procollagen type I C-terminal propeptide; C1TP, collagen type I C-terminal telopeptide; MMP-1, matrix metalloproteinase-1. Quantitative variables are expressed as mean ± SD or median (interquartile range) and categorical variables as number (percentage).

	All Patients (n = 70)	Subclinical cardiotoxicity		<i>P value</i>
		No (n = 56)	Yes (n = 14)	
RWT	0.36 ± 0.08	0.36 ± 0.08	0.35 ± 0.08	0.59
LVEDVi, mL/m ²	54.6 ± 14.6	53.4 ± 14.0	59.6 ± 16.4	0.16
LVEF, %	63.9 ± 5.1	63.8 ± 5.1	64.5 ± 5.2	0.63
E:A ratio	1.13 ± 0.35	1.16 ± 0.37	1.04 ± 0.24	0.27
DT, ms	208 ± 43.0	206 ± 44.9	216 ± 34.8	0.46
LAVI, mL/m ²	18.8 ± 5.9	19.3 ± 6.2	16.5 ± 3.9	0.11
Tissue Doppler				
E:e' ratio	6.8 ± 1.9	6.8 ± 2.0	6.7 ± 1.8	0.90
Speckle tracking				
GLS, %	-20.6 ± 2.0	-20.4 ± 2.0	-21.1 ± 2.1	0.30
3D Echocardiography				
LVEDVi, mL/m ²	47.4 ± 9.3	48.9 ± 9.4	41.6 ± 6.1	0.009
LVESVi, mL/m ²	17.7 ± 4.6	18.2 ± 4.8	15.8 ± 3.5	0.10
LVEF, %	62.5 ± 5.7	62.7 ± 5.7	61.7 ± 5.6	0.58
Biomarkers				
Cardiomyocyte stress/damage				
NTproBNP, pg/mL	40.2 (22.8–64.9)	38.6 (22.3–61.1)	59.4 (35.0–81.0)	0.10
hs-TnT, ng/L	3.0 (3.0-4.6)	3.0 (3.0-4.3)	3.0 (3.0-6.4)	0.94
Myocardial stress				
Galectin 3, ng/mL	12.8 (11.1–14.8)	12.7 (11.2–15.0)	13.2 (10.8–15.1)	0.87
sST2, ng/mL	23.7 (19.4–30.8)	23.0 (19.5–30.7)	28.0 (18.4–32.8)	0.85
Endothelial dysfunction				
VCAM-1, ng/mL	877 (739–1106)	863 (736–1024)	1044 (825–1175)	0.10

BMI means body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; LVMI, left ventricular (LV) mass index; LVH, LV hypertrophy; RWT, relative wall thickness; LVEDVi, LV end-diastolic volume index; E, maximum early transmitral flow velocity in diastole; A, maximum late transmitral flow velocity in diastole; DT, deceleration time; LAVI, left atrial volume index; e', maximum early diastolic velocity of the mitral annulus displacement; LVESVi, LV end-systolic volume index; LVEF, LV ejection fraction; NT-proBNP, amino-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; sST2, soluble suppression of tumourigenicity-2; VCAM-1, vascular cell adhesion molecule-1; PICP, procollagen type I C-terminal propeptide; C1TP, collagen type I C-terminal telopeptide; MMP-1, matrix metalloproteinase-1. Quantitative variables are expressed as mean ± SD or median (interquartile range) and categorical variables as number (percentage).

	All Patients	Subclinical cardiotoxicity		<i>P</i> value
	(n = 70)	No (n = 56)	Yes (n = 14)	
Myocardial fibrosis				
PICP, ng/mL	72.6 (59.4–87.7)	74.3 (60.4–88.3)	65.7 (57.6–77.9)	0.37
CITP:MMP1 ratio	1.5 (1.2–3.1)	1.6 (1.2–3.2)	1.4 (1.0–2.8)	0.57
BMI means body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; LVMI, left ventricular (LV) mass index; LVH, LV hypertrophy; RWT, relative wall thickness; LVEDVi, LV end-diastolic volume index; E, maximum early transmitral flow velocity in diastole; A, maximum late transmitral flow velocity in diastole; DT, deceleration time; LAVI, left atrial volume index; e', maximum early diastolic velocity of the mitral annulus displacement; LVESVi, LV end-systolic volume index; LVEF, LV ejection fraction; NT-proBNP, amino-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; sST2, soluble suppression of tumourigenicity-2; VCAM-1, vascular cell adhesion molecule-1; PICP, procollagen type I C-terminal propeptide; CITP, collagen type I C-terminal telopeptide; MMP-1, matrix metalloproteinase-1. Quantitative variables are expressed as mean $\pm$ SD or median (interquartile range) and categorical variables as number (percentage).				

Analysis of longitudinal changes with cancer therapy

All patients

Effects of chemotherapy on biochemical and echocardiographic parameters, and on biomarkers are shown in Table S1. Of interest, left atrial volume index (LAVI) and LV end-diastolic and systolic volume indexes as determined by 3D echocardiography increased at visit 2 versus baseline, and a relative reduction of GLS at visit 2 was observed compared with baseline and visit 1 (Table S1). In addition, levels of NT-proBNP, hs-TnT, sST2 and VCAM-1 were increased at visit 1 as compared with baseline (Table S1, Fig. 1B). At visit 2, NT-proBNP, hs-TnT and VCAM-1 remained elevated and PICP increased as compared with baseline (Table S1, Fig. 1B).

Patients categorized according to the presence of subclinical cardiotoxicity at visit 2

Fourteen patients (20.0%) exhibited subclinical cardiotoxicity at visit 2. Table 1 shows the baseline clinical characteristics of patients classified according to the absence or presence of subclinical cardiotoxicity at visit 2. No clinically relevant differences were observed between the two groups of patients at baseline (Table 1).

Differences at visit 1 and visit 2 in hematological, renal and liver function parameters between patients with and without subclinical cardiotoxicity are shown in supplemental Table 2. Of interest, patients with subclinical cardiotoxicity at visit 2 exhibited lower hemoglobin and hematocrit values at visit 1 than the remaining patients (*P* for interaction ≤ 0.018).

Differences at visit 1 and visit 2 in echocardiographic parameters and biomarkers between patients with and without subclinical cardiotoxicity at visit 2 are shown in Table 2. Of interest, patients with subclinical cardiotoxicity exhibited higher PICP levels at visit 2 as compared with the remaining patients (*P* for interaction < 0.001) (Table 2 and Fig. 2A). No other interactions were found significant for the remaining biomarkers (Table 2).

Table 2

Differences in biochemical and echocardiographic parameters, and in biomarkers, after treatment with epirubicin/cyclophosphamide (visit 1) followed by treatment with taxanes (visit 2) in patients with breast cancer categorized according to the absence or presence of subclinical cardiotoxicity at visit 2.

Difference vs no cardiotoxicity							P for interaction
Visit 1			Visit 2				
	Difference	95% CI	P value	Difference	95% CI	P value	
Biochemical parameters							
Hematological							
Hemoglobin, g/dL	-0.68	-1.28 to -0.08	0.026	0.18	-0.59 to 0.96	0.64	0.018
Hematocrit, %	-2.56	-4.27 to -0.84	0.003	-0.32	-1.75 to 1.10	0.66	0.002
Platelets, 10 ⁹ /L	22.8	-33.6 to 79.3	0.43	-3.17	-36.6 to 30.2	0.85	0.47
Leukocytes (log ₂), 10 ⁹ /mL	-0.02	-0.57 to 0.53	0.95	-0.08	-0.35 to 0.19	0.58	0.88
Neutrophils, %	-0.36	-8.13 to 7.41	0.93	-2.17	-11.6 to 7.26	0.65	0.92
Lymphocytes, %	-0.62	-7.69 to 6.45	0.86	0.59	-5.17 to 6.34	0.84	0.94
Monocytes, %	-0.67	-4.97 to 3.63	0.76	1.61	-1.15 to 4.38	0.25	0.55
Renal function							
eGFR, ml/min/1.73 m ²	-2.34	-6.99 to 2.30	0.32	-3.06	-7.80 to 1.69	0.21	0.49
Liver function							
AST (log ₂), IU/L	0.04	-0.31 to 0.39	0.83	-0.10	-0.38 to 0.18	0.49	0.72
ALT (log ₂), IU/L	-0.07	-0.73 to 0.59	0.83	-0.32	-0.94 to 0.31	0.32	0.75
GGT (log ₂), IU/L	-0.11	-0.85 to 0.63	0.76	-0.33	-0.85 to 0.20	0.22	0.83
ALP (log ₂), IU/L	0.04	-0.21 to 0.30	0.74	0.04	-0.15 to 0.23	0.69	0.84
Echocardiographic parameters							
2D Echocardiography and M mode							

Abbreviations as in Table 1. *Significant after Benjamini and Hochberg multiple-test correction (5% FDR) in the biomarker analyses

Difference vs no cardiotoxicity							<i>P for interaction</i>
Visit 1			Visit 2				
	Difference	95% CI	P value	Difference	95% CI	P value	
LVMI, g/m ²	-4.29	-14.3 to 5.68	<i>0.40</i>	-0.31	-10.0 to 9.40	<i>0.95</i>	<i>0.41</i>
RWT	0.02	-0.02 to 0.06	<i>0.37</i>	0.02	-0.04 to 0.07	<i>0.54</i>	<i>0.69</i>
LVEDVi, mL/m ²	-2.40	-12.0 to 7.19	<i>0.62</i>	-0.65	-10.6 to 9.27	<i>0.90</i>	<i>0.59</i>
LVEF, %	0.19	-2.30 to 2.67	<i>0.88</i>	-1.46	-4.65 to 1.73	<i>0.37</i>	<i>0.57</i>
E:A ratio	0.04	-0.19 to 0.27	<i>0.75</i>	0.002	-0.14 to 0.14	<i>0.98</i>	<i>0.78</i>
DT, ms	-7.63	-28.0 to 12.7	<i>0.46</i>	5.46	-11.6 to 22.5	<i>0.53</i>	<i>0.55</i>
LAVI, mL/m ²	-1.68	-5.63 to 2.27	<i>0.40</i>	-3.24	-7.66 to 1.18	<i>0.15</i>	<i>0.61</i>
Tissue Doppler							
E:e'	0.31	-0.80 to 1.41	<i>0.59</i>	0.08	-0.59 to 0.75	<i>0.81</i>	<i>0.85</i>
Speckle tracking							
GLS, %	0.57	-0.32 to 1.45	<i>0.21</i>	4.07	3.15 to 4.99	<i>< 0.001</i>	<i>< 0.001</i>
3D Echocardiography							
LVEDVi, mL/m ²	-3.07	-9.03 to 2.88	<i>0.31</i>	3.26	-2.24 to 8.77	<i>0.25</i>	<i>0.06</i>
LVESVi, mL/m ²	-1.93	-4.55 to 0.70	<i>0.15</i>	1.91	-1.40 to 5.21	<i>0.26</i>	<i>0.049</i>
LVEF, %	1.73	-1.31 to 4.78	<i>0.27</i>	-4.69	-9.86 to 0.47	<i>0.08</i>	<i>0.001</i>
Biomarkers (log ₂)							
Cardiomyocyte stress/damage							
NTproBNP, pg/mL	0.49	-0.02 to 1.00	<i>0.06</i>	0.44	-0.10 to 0.99	<i>0.11</i>	<i>0.53</i>
hs-TnT, ng/L	-0.03	-0.70 to 0.64	<i>0.93</i>	0.13	-0.32 to 0.59	<i>0.56</i>	<i>0.82</i>

Abbreviations as in Table 1. *Significant after Benjamini and Hochberg multiple-test correction (5% FDR) in the biomarker analyses

Difference vs no cardiotoxicity							<i>P for interaction</i>
Visit 1			Visit 2				
	Difference	95% CI	P value	Difference	95% CI	P value	
Myocardial stress							
Galectin 3, ng/mL	0.004	-0.19 to 0.20	0.97	-0.03	-0.31 to 0.25	0.82	0.92
sST2, ng/mL	0.27	-0.32 to 0.85	0.37	-0.06	-0.35 to 0.24	0.71	0.54
Endothelial dysfunction							
VCAM-1, ng/mL	0.005	-0.10 to 0.11	0.93	0.10	-0.10 to 0.30	0.32	0.39
Myocardial fibrosis							
PICP, ng/mL	-0.12	-0.34 to 0.09	0.26	0.57	0.27 to 0.87	< 0.001*	< 0.001*
CITP, ng/mL	0.10	-0.22 to 0.42	0.54	0.24	-0.08 to 0.57	0.14	0.45
CITP:MMP-1 ratio	-0.34	-0.81 to 0.13	0.15	-0.08	-0.65 to 0.48	0.77	0.62
Abbreviations as in Table 1. *Significant after Benjamini and Hochberg multiple-test correction (5% FDR) in the biomarker analyses							

Of the 14 patients with subclinical cardiotoxicity at visit 2, three patients presented a reduction of LVEF > 10% versus baseline to a value lower than 53% and 4 patients exhibited LVEF reductions > 15% as compared with baseline. Of interest, these patients exhibited higher PICP levels at visit 2 (mean [95%CI]: 175 [103–208] ng/mL) as compared with patients without cardiotoxicity (86.5 [70.2–113] ng/mL) (Difference values [$\log_2$] = 0.66 [95%CI :0.24 to 1.09], *P* for interaction = 0.002).

Analyses of associations

Univariable linear relationships between levels of the biomarkers that showed variations across visits and all echocardiographic parameters were evaluated in all patients (Table S2). Of interest, NT-proBNP, hs-TnT, VCAM-1 and PICP exhibited a direct association with a relative reduction of GLS along chemotherapy (Table S2).

To identify factors independently associated with the relative reduction of GLS, we conducted multivariable linear mixed regression analyses including all characteristics associated with this echocardiographic parameter (defined as $P \leq 0.10$ in univariable analysis) as shown in Table 3. The final model revealed that, along with NT-proBNP, a progressive increment in PICP levels is an independent significant predictor of the relative reduction of GLS over the course of chemotherapy (Fig. 2B, Table 3).

Table 3

Univariable and multivariable linear mixed model analyses for the associations with global longitudinal strain in patients with breast cancer

	Univariable		Multivariable	
	Estimate (95%CI)	P value	Estimate (95%CI)	P value
Age, years	0.02 (-0.02 to 0.06)	<i>0.34</i>		
BMI, kg/m ²	0.11 (0.02 to 0.19)	<i>0.011</i>	0.04 (-0.06 to 0.15)	<i>0.38</i>
Left breast, yes/no	-0.17 (-1.06 to 0.73)	<i>0.71</i>		
Ki67, %	-0.003 (-0.02 to 0.02)	<i>0.76</i>		
ER and/or PR positive, yes/no	-0.21 (-1.28 to 0.86)	<i>0.70</i>		
TNM Stages	-0.03 (-0.26 to 0.21)	<i>0.83</i>		
≥Median cumulative dose, yes/no				
Epirubicin ≥ 377 mg/m ²	-0.83 (-1.69 to 0.04)	<i>0.061</i>	-0.30 (-1.22 to 0.62)	<i>0.52</i>
Cyclophosphamide ≥ 3820 mg/m ²	1.03 (0.18 to 1.89)	<i>0.017</i>	1.05 (0.17 to 1.92)	<i>0.020</i>
Paclitaxel, yes/no	-0.06 (-1.24 to 1.12)	<i>0.92</i>		
Other treatments, yes/no				
Carboplatin	0.03 (-0.89 to 0.95)	<i>0.95</i>		
Trastuzumab ± Pertuzumab	-0.27 (-1.27 to 0.73)	<i>0.59</i>		
Surgery	0.48 (-0.35 to 1.31)	<i>0.26</i>		
Radiotherapy	1.11 (-0.02 to 2.24)	<i>0.054</i>	0.32 (-0.93 to 1.57)	<i>0.62</i>
Comorbidities, yes/no				
Hypertension	1.27 (0.06 to 2.49)	<i>0.040</i>	-0.11 (-1.33 to 1.11)	<i>0.86</i>
Obesity	0.98 (-0.06 to 2.02)	<i>0.064</i>		
Dyslipemia	1.42 (0.14 to 2.71)	<i>0.030</i>	0.33 (-0.81 to 1.47)	<i>0.57</i>
Current smoking	0.57 (-0.85 to 1.99)	<i>0.43</i>		
Hematological parameters				
Hemoglobin, g/dL	-0.11 (-0.24 to 0.03)	<i>0.11</i>		
Hematocrit, %	-0.05 (-0.10 to 0.008)	<i>0.022</i>	0.01 (-0.06 to 0.07)	<i>0.90</i>
Platelets, 10 ⁹ /L	-0.001 (-0.005 to 0.002)	<i>0.42</i>		
Leukocytes (log ₂), 10 ⁹ /mL	-0.41 (-0.97 to 0.14)	<i>0.14</i>		
Neutrophils, %	0.007 (-0.01 to 0.02)	<i>0.40</i>		
Lymphocytes, %	-0.02 (-0.04 to 0.002)	<i>0.09</i>	-0.01 (-0.04 to 0.02)	<i>0.45</i>
Abbreviations as in Table 1.				

	Univariable	Multivariable		
Monocytes, %	0.02 (-0.03 to 0.07)	<i>0.47</i>		
Renal function parameters				
eGFR, mL/min/1.73 m ²	-0.01 (-0.03 to 0.01)	<i>0.14</i>		
Liver function parameters				
AST (log ₂), IU/L	0.18 (-0.46 to 0.81)	<i>0.59</i>		
ALT (log ₂), IU/L	0.11 (-0.27 to 0.49)	<i>0.58</i>		
GGT (log ₂), IU/L	-0.02 (-0.24 to 0.20)	<i>0.86</i>		
ALP (log ₂), IU/L	0.66 (0.12 to 1.20)	<i>0.017</i>	0.10 (-0.67 to 0.86)	<i>0.80</i>
Baseline GLS $\geq$ -17%	3.59 (2.98 to 4.19)	<i>< 0.001</i>	2.98 (1.33 to 4.62)	<i>< 0.001</i>
Biomarkers				
NT-proBNP (log ₂), pg/mL	0.35 (0.10 to 0.60)	<i>0.006</i>	0.31 (0.006 to 0.61)	<i>0.046</i>
hs-TnT (log ₂), ng/L	0.34 (0.05 to 0.64)	<i>0.024</i>	0.21 (-0.15 to 0.56)	<i>0.26</i>
VCAM (log ₂), ng/mL	1.06 (0.20 to 1.92)	<i>0.016</i>	0.57 (-0.39 to 1.52)	<i>0.24</i>
PICP (log ₂), ng/mL	0.94 (0.43 to 1.45)	<i>< 0.001</i>	0.97 (0.43 to 1.51)	<i>< 0.001</i>
Abbreviations as in Table 1.				

The associations of biomarker values at baseline or interval changes across visits with subclinical cardiotoxicity at visit 2 were estimated by univariable logistic regression analyses (Table S3). As shown in the table, only the increments in PICP between baseline and visit 2 and between visit 1 and visit 2 were significantly associated with subclinical cardiotoxicity (Table S3). Specifically, there was more than a 3-fold increase in the risk of subclinical cardiotoxicity for each increase in 1 SD of PICP change at visit 2 versus baseline (which corresponded to a PICP increment of 58%) or versus visit 1 (which corresponded to a PICP increment of 65%) (Table S3). Of note, the associations between PICP changes (per 1SD) and the risk of subclinical cardiotoxicity were independent of the declines at visit 1 in hemoglobin (visit 2 vs baseline: OR = 4.42[95%CI: 1.70–11.5], *P* = 0.002; visit 2 vs visit 1: OR = 5.14[95%CI: 2.02–13.1], *P* = 0.001) and in the hematocrit percentage (visit 2 vs baseline: OR = 4.55[95%CI: 1.64–12.6], *P* = 0.004; visit 2 vs visit 1: OR = 5.52[95%CI: 1.99–15.3], *P* = 0.001), as the only parameters exhibiting significant interactions with subclinical cardiotoxicity (Table 2).

ROC analyses showed significant diagnostic performances for PICP increments at visit 2 vs baseline or a visit 2 vs visit 1 to predict subclinical cardiotoxicity (visit 2 vs baseline: AUC = 0.800 [95%CI: 0.639–0.960], *P* = 0.001; visit 2 vs visit 1: AUC = 0.819 [95%CI: 0.687–0.951], *P* < 0.001) (Fig. 3), with cut-off values of 65.3% (79% sensitivity, 82% specificity) and of 105% (64% sensitivity, 87% specificity) respectively. In addition, PICP increments at visit 2 vs baseline predicted cardiotoxicity as assessed by a decrease in LVEF (AUC = 0.805 [95%CI: 0.586–1.0], *P* = 0.008).

Study 2: Patients with HF

Characteristics of patients at baseline

As shown in Table 4, all HF etiology groups were matched for age, sex, body mass index, potassium levels, eGFR, NYHA class, HF duration, number of previous hospitalizations, LVEF, and NT-proBNP levels. ACC-HF patients exhibited lower prevalence of atrial fibrillation as compared with HHD and VHD groups, and lower prevalence of hypercholesterolemia and frequency of treatment with statins and nitrates compared with patients with IHD. As for the remaining clinical characteristics, ACC-HF patients were matched with all groups (Table 4). Of interest, PICP levels were similar in all HF etiologies (Table 4).

Table 4
Clinical characteristics of heart failure patients categorized according to different etiologies

	IHD (n = 65)	DCM (n = 85)	HHD (n = 47)	VHD (n = 45)	Other (n = 68)	ACC- HF (n = 37)	<i>P</i> value
Age, years	61.5 ± 10.1	62.9 ± 14.1	65.3 ± 12.2	66.6 ± 8.8	62.2 ± 12.7	60.0 ± 11.7	0.11
Female gender, n (%)	49 (75.4)	64 (75.3)	30 (63.8)	28 (62.2)	48 (70.6)	30 (81.1)	0.30
BMI, kg/m ²	27.1 ± 4.7	27.5 ± 5.6	28.8 ± 5.9	26.7 ± 5.1	28.1 ± 5.6	28.2 ± 5.3	0.42
Sodium, mmol/L	137 ± 3.2	138 ± 3.1	139 ± 4.1*	138 ± 3.4	138 ± 3.5	139 ± 2.7	0.002
Potassium, mmol/L	4.1 ± 0.5	4.2 ± 0.5	4.3 ± 0.6	4.2 ± 0.4	4.3 ± 0.6	4.2 ± 0.5	0.31
Hemoglobin, g/dL	12.4 ± 1.8 [†]	13.5 ± 1.7	13.4 ± 1.7	12.3 ± 1.7 [†]	12.9 ± 1.7	12.5 ± 1.6	< 0.001
eGFR, mL/min/1.73 m ²	76.2 ± 25.7	68.0 ± 28.6	64.2 ± 24.4	62.0 ± 26.3	70.9 ± 27.9	67.9 ± 30.8	0.10
NYHA class, n (%)							
III-IV	12 (18.5)	20 (23.5)	16 (34.0)	14 (31.1)	12 (17.6)	11 (29.7)	0.22
HF duration, months	3.0(1.0-25.5)	8.0(2.0-48.0)	6.0(1.0-25.2)	9.0(2.0-36.0)	3.5(1.3-17.0)	2(1.0-20.5)	0.10
≥ 2 previous hospitalizations, n (%)	12 (18.5)	11 (13.3)	7 (14.9)	11 (24.4)	10 (14.7)	4 (10.8)	0.57
Comorbidities, n (%)							
Atrial fibrillation	6 (9.2)	16 (18.8)	15 (31.9) [‡]	22 (48.9) [§]	14 (20.6)	1 (2.7)	< 0.001
Hypercholesterolemia	44 (67.7)	47 (55.3)	20 (42.6)	21 (46.7)	42 (61.8)	14 (37.8)*	0.016
Peripheral vascular disease	7 (10.8)	5 (5.9)	1 (2.1)	5 (11.1)	0 (0.0)	1 (2.7)	0.06

IHD means ischemic heart disease; DCM, diabetic cardiomyopathy; HHD, hypertensive heart disease; VHD, valvular heart disease; ACC-HF, anthracycline-based chemotherapy-induced heart failure; eGFR, estimated glomerular filtration rate; BMI, body mass index; NYHA, New York Heart Association; HF, heart failure; COPD; chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blockers; MR, mineralocorticoid receptor; LVEDD, left ventricular (LV) end-diastolic diameter; LVESD, LV end-systolic diameter; LVFS; LV fractional shortening; LVEF, LV ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PICP, procollagen type I C-terminal propeptide. Quantitative variables are expressed as mean ± SD or as median (interquartile range). Categorical variables are expressed as numbers (percentages). Bonferroni correction was performed for post-hoc analyses. *P < 0.05 vs IHD, [†]P < 0.05 vs DCM and HHD, [‡]P < 0.05 vs IHD and ACC-HF, [§]P < 0.05 vs IHD, DCM, ACC-HF and others, ^{||}P < 0.05 vs IHD, DCM, VHD and others, [#]P < 0.05 vs all, ^{**}P < 0.05 vs DCM, VHD, ACC-HF and others

	IHD (n = 65)	DCM (n = 85)	HHD (n = 47)	VHD (n = 45)	Other (n = 68)	ACC- HF (n = 37)	<i>P</i> value
COPD	4 (6.2)	8 (9.4)	4 (8.5)	4 (8.9)	10 (14.7)	0 (0.0)	0.17
Treatments, n(%)							
ACEIs/ARBs	62 (95.4)	75 (88.2)	37 (78.7)	36 (80.0)	60 (88.2)	32 (86.5)	0.11
Beta-Blockers	64 (98.5)	80 (94.1)	40 (85.1)	38 (84.4)	61 (89.7)	34 (91.9)	0.07
Diuretics	58 (89.2)	75 (88.2)	39 (83.0)	43 (95.6)	60 (88.2)	28 (75.7)	0.14
MR Blockers	58 (89.2)	67 (78.8)	16 (34.0)	30 (66.7)	48 (70.6)	24 (64.9)	< 0.001
Digoxin	13 (20.0)	30 (35.3)	19 (40.4)	22 (48.9)*	23 (33.8)	9 (21.6)	0.018
Statins	62 (95.4) [#]	61 (74.1)	26 (55.3)	30 (66.7)	44 (64.7)	20 (54.1)	< 0.001
Nitrates	32 (49.2) ^{**}	21 (24.7)	13 (27.7)	10 (22.2)	13 (19.1)	7 (18.9)	0.001
Echocardiographic parameters							
LVEDD, mm	56.8 ± 7.7	61.1 ± 7.0*	57.8 ± 9.3	56.7 ± 11.1	56.9 ± 10.0	57.4 ± 7.1	0.023
LVESD, mm	44.4 ± 9.1	50.0 ± 8.6*	47.7 ± 10.6	43.7 ± 13.4	44.8 ± 12.2	46.0 ± 8.9	0.008
LVFS, %	22.4 ± 8.6	18.8 ± 7.4	20.3 ± 7.7	23.7 ± 13.0	22.5 ± 10.6	20.1 ± 9.4	0.18
LVEF, %	34.6 ± 9.8	33.8 ± 10.8	38.8 ± 13.8	39.5 ± 14.8	38.3 ± 14.9	36.4 ± 14.0	0.18
Biomarkers							
NT-proBNP, pg/mL	1740(773–2997)	1081(510–2169)	1468(553–2645)	1646(693–6545)	1118(473–3191)	1539 (495–3150)	0.19

IHD means ischemic heart disease; DCM, diabetic cardiomyopathy; HHD, hypertensive heart disease; VHD, valvular heart disease; ACC-HF, anthracycline-based chemotherapy-induced heart failure; eGFR, estimated glomerular filtration rate; BMI, body mass index; NYHA, New York Heart Association; HF, heart failure; COPD; chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blockers; MR, mineralocorticoid receptor; LVEDD, left ventricular (LV) end-diastolic diameter; LVESD, LV end-systolic diameter; LVFS; LV fractional shortening; LVEF, LV ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PICP, procollagen type I C-terminal propeptide. Quantitative variables are expressed as mean ± SD or as median (interquartile range). Categorical variables are expressed as numbers (percentages). Bonferroni correction was performed for post-hoc analyses. *P < 0.05 vs IHD, [†]P < 0.05 vs DCM and HHD, [‡]P < 0.05 vs IHD and ACC-HF, [§]P < 0.05 vs IHD, DCM, ACC-HF and others, ^{||}P < 0.05 vs IHD, DCM, VHD and others, [#]P < 0.05 vs all, ^{**}P < 0.05 vs DCM, VHD, ACC-HF and others

	IHD (n = 65)	DCM (n = 85)	HHD (n = 47)	VHD (n = 45)	Other (n = 68)	ACC- HF (n = 37)	<i>P</i> value
PICP, ng/mL	104(85.2– 159)	103(83.3– 128)	100(83.9– 125)	120(91.1– 160)	104(79.8– 129)	118 (94.9– 151)	0.25
<p>IHD means ischemic heart disease; DCM, diabetic cardiomyopathy; HHD, hypertensive heart disease; VHD, valvular heart disease; ACC-HF, anthracycline-based chemotherapy-induced heart failure; eGFR, estimated glomerular filtration rate; BMI, body mass index; NYHA, New York Heart Association; HF, heart failure; COPD; chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blockers; MR, mineralocorticoid receptor; LVEDD, left ventricular (LV) end-diastolic diameter; LVESD, LV end-systolic diameter; LVFS; LV fractional shortening; LVEF, LV ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PICP, procollagen type I C-terminal propeptide. Quantitative variables are expressed as mean ± SD or as median (interquartile range). Categorical variables are expressed as numbers (percentages). Bonferroni correction was performed for post-hoc analyses. *<i>P</i> < 0.05 vs IHD, [†]<i>P</i> < 0.05 vs DCM and HHD, [‡]<i>P</i> < 0.05 vs IHD and ACC-HF, [§]<i>P</i> < 0.05 vs IHD, DCM, ACC-HF and others, <i>P</i> < 0.05 vs IHD, DCM, VHD and others, [#]<i>P</i> < 0.05 vs all, ^{**}<i>P</i> < 0.05 vs DCM, VHD, ACC-HF and others</p>							

Analysis of associations

Univariable linear relationships showed that NT-proBNP and PICP exhibited inverse associations with LVEF in ACC-HF patients (Table 5). Of interest, PICP association with LVEF in these patients was independent of NT-proBNP levels (Table 5). In addition, whereas NT-proBNP was inversely associated with LVEF also in HF patients of DCM and HHD origin, no other association was found between PICP and LVEF in the remaining HF etiologies (Table 5).

Table 5
Associations between NT-proBNP, PICP and LVEF in patients with heart failure

LVEF, %				
	Estimate	95% CI	R ²	P value
Independent variables				
NT-proBNP (log₂), ng/mL				
<i>Etiologies</i>				
IHD	-0.70	-2.39 to 1.00	0.01	0.41
DCM	-1.05	-2.09 to -0.004	0.05	0.049
HHD	-3.48	-5.84 to -1.12	0.17	0.005
VHD	-1.05	-3.03 to 0.92	0.03	0.29
Others	0.03	-1.80 to 1.85	< 0.001	0.98
ACC-HF	-2.80	-4.44 to -1.17	0.26	0.001
PICP (log₂), ng/mL				
<i>Etiologies</i>				
IHD	-0.42	-4.49 to 3.65	< 0.01	0.84
DCM	1.16	-3.45 to 5.77	< 0.01	0.62
HHD	-0.14	-10.7 to 10.4	< 0.01	0.98
VHD	-3.41	-10.2 to 3.42	0.02	0.32
Others	1.77	-4.39 to 7.92	< 0.01	0.57
ACC-HF	-10.5	-17.4 to -3.66	0.22	0.004*
Abbreviations as in Table 4. *P = 0.022 after adjustment by NT-proBNP (Estimate [95%CI]= -7.77 [-14.4 to -1.18]; model R ² = 0.36)				

Analysis of LVEF longitudinal changes over one year

LVEF was measured at 12 months after recruitment in 33 ACC-HF patients. These patients were categorized according to baseline PICP tertiles in patients with low (1st tertile: <100 ng/mL, n = 11), medium (2nd tertile: 100–129 ng/mL, n = 11) and high (3rd tertile: >129 ng/mL, n = 11) PICP levels. As shown in Fig. 4, baseline LVEF-adjusted analyses revealed that, after one year, LVEF improved in patients with low or medium PICP but remained unchanged in those with high PICP levels at baseline.

Study 3: In vitro findings

In a first step, dose-response curves were performed for doxorubicin, cyclophosphamide, paclitaxel and trastuzumab in HDFs (Fig. 5). Concentrations with significant submaximal effects on cell viability and procollagen type-I mRNA expression, and two lower doses, were chosen for each agent to be tested in HCFs. As shown in Table S4, all agents

decreased the number of cells and increased SMA mRNA expression as compared with control in HCFs. In addition, doxorubicin, cyclophosphamide and trastuzumab, but not paclitaxel, increased the expression of procollagen type-I mRNA as compared with control (Fig. 6A-C). Moreover, these three compounds increased the expression of PCP and increased the extracellular protein levels of collagen and PICP (Fig. 6D-F), as well as LOX activity (Table S4). Finally, doxorubicin and cyclophosphamide increased the expression of PCPE, and cyclophosphamide and trastuzumab increased LOX mRNA expression, as compared with control (Table S4).

Discussion

The major findings of this study are the following: 1) In patients with breast cancer there was a relative GLS reduction accompanied by increments in serum NT-proBNP, hs-TnT, VCAM-1 and PICP after 6 months-chemotherapy, without changes in the remaining biomarkers; 2) PICP increment after chemotherapy was more pronounced in the subset of patients who developed subclinical cardiotoxicity; 3) Levels of PICP were directly and independently associated with the relative GLS reduction over the course of chemotherapy; 4) Levels of PICP were inversely associated with LVEF in ACC-HF patients; 5) High levels of PICP at baseline were associated with lack of LVEF improvement after 12 months in ACC-HF patients; and 6) the cardiotoxic agents doxorubicin, cyclophosphamide and trastuzumab stimulated the differentiation of HCFs to a myofibroblast collagen-synthesizing phenotype. To our knowledge, this is the first study evaluating the effects of cancer chemotherapy on myocardial collagen, as assessed non-invasively by using circulating biomarkers associated with histologically-proven MIF. In addition, to the best of our knowledge, this is the first time that the effects of chemotherapy agents on collagen metabolism have been evaluated in HCFs.

It has been widely demonstrated that NT-proBNP and hs-TnT levels increase during cancer therapy, although their utility for cardiotoxicity prediction has been recently questioned.^{21,30-32} In this study, we have reported chemotherapy-induced increments in these biomarkers associated with a reduction of LV contractility, although the association shown by hs-TnT was not independent of confounding factors. On the other hand, conflicting results have been shown regarding longitudinal changes in circulating VCAM-1, galectin-3 and sST2 during cancer treatment,^{30,32,33} thus further studies are necessary to confirm the influence of oncologic therapy on the serum levels of these proteins. The current study is the first to report that anthracycline-based-chemotherapy for breast cancer increases the circulating levels of a biomarker that reflects increased collagen deposition in the myocardium,¹⁶ being this increase particularly evident in patients developing subclinical cardiotoxicity. In addition, we have found an association between biomarker-assessed myocardial collagen content and a reduction of LV contractility along chemotherapy, independently of relevant clinical factors including chemotherapy cumulative doses and biomarkers of cardiomyocyte damage. Importantly, this association between biomarker-assessed MIF and decreased LV contractility was further confirmed in patients with ACC-HF. Even more, longitudinal pilot observations in these patients suggest that the degree of MIF at baseline may influence evolution of LV function over time.

These findings reinforce the notion that, not only the cardiomyocyte injury, but also the presence of MIF seems to be relevant for the impairment of LV contractile function in cancer patients treated with anthracycline-based chemotherapy.⁷ Mechanistically, these effects combined may result in larger accumulation of collagen encircling cardiac muscle with reduced functionality, further restricting the stretching of muscle fibers and impairing the direct cell-to-cell communication necessary for synchronous activation of cardiomyocytes.³⁴ In this regard, several studies demonstrate a detrimental effect of MIF on the deformation of the LV wall (i.e. reduced GLS), in experimental models³⁵ and in patients with different cardiomyopathies.³⁶⁻³⁹ Of notice, the PICP levels here observed in breast cancer patients with cardiotoxicity and in patients with ACC-HF were similar to those found in hypertensive heart failure patients with severe MIF.⁴⁰ It is also important to acknowledge the potential influence of a systemic reparative

response after ACC treatment on the levels of serum PICP, with activation of fibrotic processes in organs other than the heart. In this regard, it has been shown that anti-cancer therapies may cause arterial stiffness, with increased collagen production suggested as a potential mechanism, among others, underlying this vascular alteration.^{41,42} Since arterial stiffness contributes to LVD, we cannot discard that the association found between PICP with LVD in ACC-treated patients is reflecting the combined interaction of cardiac and vascular fibrosis.

Although several studies have reported profibrotic effects of anthracyclines, cyclophosphamide, paclitaxel and trastuzumab in the myocardium of experimental models of cardiotoxicity,^{8–14} and in rodent cardiac fibroblasts,^{9,11} the role of these agents in HCFs has not been characterized. In this regard, we describe that doxorubicin, cyclophosphamide and trastuzumab stimulated the differentiation to a myofibroblast collagen-synthesizing phenotype, including enhanced presence of PICP in the extracellular medium. Therefore, we may speculate that cardiotoxic agents used to treat breast cancer may directly stimulate HCFs differentiation and collagen fiber synthesis and deposition. In this regard, it has been suggested that the anthracycline profibrotic effects are mediated through substance P, ROS, STAT3 and atypical G protein Gβ₅-related mechanisms.^{9,11} In addition, cyclophosphamide has been shown to induce human lung fibroblasts premature senescence by activating the MAP kinase signaling pathway.⁴³ Whether these pathways are involved in the pro-fibrotic actions exerted by these agents in HCFs require further studies.

Some limitations of the present study must be acknowledged. First, small sample size may have constrained statistical power to detect differences in the different biomarkers assessed in patients with breast cancer, and preclude from adequately assess the impact of potential confounders in the association and longitudinal analyses in ACC-HF patients. Second, there is lack of follow-up information beyond the considered treatment period in patients with breast cancer, but long-term follow-up is planned and ongoing. Third, serum samples after 1-year follow-up were not available to measure PICP in ACC-HF patients. Fourth, our data cannot be extrapolated to oncologic patients treated with other anti-cancer drugs different from those evaluated in this study. Fifth, because they are descriptive in nature, the associations found between PICP and cardiotoxicity do not establish causality. Finally, we cannot discard extra-cardiac sources of PICP. In this regard, determining the extracellular volume fraction in the myocardium by means of cardiac magnetic resonance could have enriched the description of the influence of myocardial fibrosis on PICP serum levels in ACC-treated patients.

In summary, this study shows for the first time that the circulating biomarker of myocardial collagen type-I deposition, PICP, is elevated in the blood of women receiving breast cancer anthracycline-based chemotherapy. In addition, we report that PICP increment is particularly pronounced in those patients with signs of early LV dysfunction, being the levels of this peptide directly and independently associated with a reduction of LV contractility along chemotherapy. Moreover, we confirm the association of PICP with LV contractile dysfunction in patients with ACC-HF, with high levels of this peptide associated with a lack of improvement in LV contractility over time. Finally, we show for the first time that anthracyclines, cyclophosphamide and trastuzumab exert profibrotic actions, particularly increasing collagen type-I synthesis, in HCFs. These results provide additional evidence for MIF as a cardiotoxic side-effect of anthracycline-based breast cancer treatment, and allow us to speculate that this lesion may be a pathophysiological mechanism underlying LVD in these patients. Finally, these preliminary findings should be considered in the context of a pilot hypothesis-generating study supporting the need of further studies designed to evaluate the prognostic potential of PICP, either by itself or combined with other biomarkers of myocardial remodeling, to monitor cardiotoxicity in larger cohorts of patients under chemotherapy.

Declarations

Ethical approval:

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Investigation Ethics Committees of the University of Navarra and of the Hospital Universitari Germans Trias i Pujol. All study procedures were in accordance with the ethical standards outlined in the Helsinki Declaration of 1975 as revised in 1983.

Consent for publication:

Not applicable

Data availability:

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Conflict of interest:

AB-G has received honoraria for lectures and advisory boards for Novartis, Vifor, Boehringer Ingelheim, Roche Diagnostics and Critical Diagnostics. The remaining authors have nothing to disclose.

Funding information:

This work was supported by the Ministry of Economy and Competitiveness, Spain (Instituto de Salud Carlos III: CB16/11/00483, PI17/01999 and PI18/01469 co-financed by FEDER funds), the Ministerio de Educación y Ciencia (SAF2017-84324-C2-1-R to A.B-G.), CIBER Cardiovascular (CB16/11/00403 to A.B-G.), and AdvanceCat (2014-2020 to A.B-G.).

Author contributions:

A.F., M.S. and J.M.A. co-designed the study, made substantial contributions to the acquisition of data and revised the manuscript critically for important intellectual content; A.F. and A.D. did the echocardiographic analyses; J.L., G.C., B.L., J.M.L.P., G.R., made substantial contributions to the acquisition of data and revised the manuscript critically for important intellectual content; S.R. analysed and interpreted the data, and drafted the work; J.D., A.G., A.B-G., and S.R. co-designed the study, acquired funding and provided resources, edited the manuscript and revised the manuscript critically for important intellectual content. All Authors have given their final approval of the version to be submitted.

Acknowledgements:

The authors thank Sonia Martínez and Ana Igea for their valuable technical assistance, the patients for their participation and the Biobank of the University of Navarra for its collaboration.

References

1. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017;35:893-911. <https://doi.org/10.1200/JCO.2016.70.5400>.
2. Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. *Epidemiology*. 2016;27:6-13. <https://doi.org/10.1097/EDE.0000000000000394>.
3. Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, Grobbee DE, Verkooijen HM. Risk of death from cardiovascular disease following breast cancer: a systematic review. *Breast Cancer Res Treat*. 2017;164:537-555. <https://doi.org/10.1007/s10549-017-4282-9>.
4. Patnaik JL, Byers T, DiGuseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. *Breast Cancer Res*. 2011;13:R64. <https://doi.org/10.1186/bcr2901>.
5. Anker MS, Hadzibegovic S, Lena A, Belenkov Y, Bergler-Klein J, de Boer RA, Farmakis D, von Haehling S, Iakobishvili Z, Maack C, Pudil R, Skouri H, Cohen-Solal A, Tocchetti CG, Coats AJS, Seferović PM, Lyon AR. Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019. *ESC Heart Fail*. 2019;6:1140-1148. <https://doi.org/10.1002/ehf2.12551>.
6. Ausoni S, Calamelli S, Saccà S, Azzarello G. How progressive cancer endangers the heart: an intriguing and underestimated problem. *Cancer Metastasis Rev*. 2020;39:535-552. <https://doi.org/10.1007/s10555-020-09869-8>.
7. Meléndez GC and Hundley WG. Is Myocardial Fibrosis a New Frontier for Discovery in Cardiotoxicity Related to the Administration of Anthracyclines? *Circ Cardiovasc Imaging*. 2016;9:e005797. <https://doi.org/10.1161/CIRCIMAGING.116.005797>.
8. Gyöngyösi M, Lukovic D, Zlabinger K, Spannauer A, Gugerell A, Pavo N, Traxler D, Pils D, Maurer G, Jakab A, Riesenhuber M, Pircher A, Winkler J, Bergler-Klein J. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. *Cardiovasc Res*. 2020;116:970-982. <https://doi.org/10.1093/cvr/cvz192>.
9. Levick SP, Soto-Pantoja DR, Bi J, Hundley WG, Widiapradja A, Manteufel EJ, Bradshaw TW, Meléndez GC. Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts. *Heart Lung Circ*. 2019;28:1598-1605. <https://doi.org/10.1016/j.hlc.2018.08.003>.
10. Russo M, Guida F, Paparo L, Trinchese G, Aitoro R, Avagliano C, Fiordelisi A, Napolitano F, Mercurio V, Sala V, Li M, Sorriento D, Ciccarelli M, Ghigo A, Hirsch E, Bianco R, Iaccarino G, Abete P, Bonaduce D, Calignano A, Berni Canani R, Tocchetti CG. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. *Eur J Heart Fail*. 2019;21:519-528. <https://doi.org/10.1002/ehf.1439>.
11. Chakraborti S, Pramanick A, Saha S, Roy SS, Chaudhuri AR, Das M, Ghosh S, Stewart A, Maity B. Atypical G Protein $\beta 5$ Promotes Cardiac Oxidative Stress, Apoptosis, and Fibrotic Remodeling in Response to Multiple Cancer Chemotherapeutics. *Cancer Res*. 2018;78:528-541. <https://doi.org/10.1158/0008-5472.CAN-17-1280>.
12. Iqbal A, Sharma S, Ansari MA, Najmi AK, Syed MA, Ali J, Alam MM, Ahmad S, Haque SE. Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice. *Eur J Pharmacol*. 2019;863:172666. <https://doi.org/10.1016/j.ejphar.2019.172666>.
13. Liu Y, Tan D, Shi L, Liu X, Zhang Y, Tong C, Song D, Hou M. Blueberry Anthocyanins-Enriched Extracts Attenuate Cyclophosphamide-Induced Cardiac Injury. *PLoS One*. 2015;10:e0127813. <https://doi.org/10.1371/journal.pone.0127813>.
14. Coppola C, Riccio G, Barbieri A, Monti MG, Piscopo G, Rea D, Arra C, Maurea C, De Lorenzo C, Maurea N. Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool

- 2D-speckle tracking. *Onco Targets Ther.* 2016;9:6785-6794. <https://doi.org/10.2147/OTT.S106528>.
15. González A, Schelbert EB, Díez J, Butler J. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. *J Am Coll Cardiol.* 2018;71:1696-1706. <https://doi.org/10.1016/j.jacc.2018.02.021>.
 16. López B, Querejeta R, González A, Larman M, Díez J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. *Hypertension.* 2012;60:677–83. <https://doi.org/10.1161/HYPERTENSIONAHA.112.196113>.
 17. López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G, Larman M, Querejeta R, Díez J. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. *J Am Coll Cardiol.* 2016;67:251–260. <https://doi.org/10.1016/j.jacc.2015.10.063>.
 18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015;28:1-39. doi: 10.1016/j.echo.2014.10.003.
 19. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, Pedri S, Ito Y, Abe Y, Metz S, Song JH, Hamilton J, Sengupta PP, Kolias TJ, d'Hooge J, Aurigemma GP, Thomas JD, Badano LP. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging.* 2015;16:1-11. doi: 10.1093/ehjci/jeu184.
 20. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J.* 2016;37:2768-2801. <https://doi.org/10.1093/eurheartj/ehw211>.
 21. Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, et al. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. *JACC Heart Fail.* 2019;7:795-804. <https://doi.org/10.1016/j.jchf.2019.04.014>.
 22. Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, Vila J, Peñafiel J, Urrutia A, Ferrer E, Vallejo N, Januzzi JL, Bayes-Genis A. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. *Int J Cardiol.* 2015;184:37-343. <https://doi.org/10.1016/j.ijcard.2015.02.019>.
 23. Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. *Eur J Pharm Sci.* 2010;41:458-463. <https://doi.org/10.1016/j.ejps.2010.07.015>.
 24. Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, Ahmed KZ, Ahmad HR, Cascorbi I. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. *Eur J Clin Pharmacol.* 2012;68:389-395. doi: 10.1007/s00228-011-1134-0.
 25. Stage TB, Bergmann TK, Kroetz DL. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. *Clin Pharmacokinet.* 2018;57:7-19. <https://doi.org/10.1007/s40262-017-0563-z>.
 26. Jamieson D, Cresti N, Verrill MW, Boddy AV. Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. *J Immunol Methods.* 2009;345:106-11. <https://doi.org/10.1016/j.jim.2009.04.006>.
 27. González García J, Gutiérrez Nicolás F, Nazco Casariego GJ, Batista López JN, Ceballos Lenza I, Ramos Díaz R, Llabrés Martínez M. Influence of Anthropometric Characteristics in Patients With Her2-Positive Breast Cancer on

Initial Plasma Concentrations of Trastuzumab. *Ann Pharmacother.* 2017;51:976-980.
<https://doi.org/10.1177/1060028017715727>.

28. López B, González A, Querejeta R, Larman M, Rábago G, Díez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. *Hypertension.* 2014;63:483-489.
<https://doi.org/10.1161/HYPERTENSIONAHA.113.02654>.
29. López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, Gallego I, Zudaire A, Brugnolaro C, Querejeta R, Larman M, Tschöpe C, Díez J. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? *Cardiovasc Res.* 2013;99:111-120. <https://doi.org/10.1093/cvr/cvt100>.
30. Tan LL, Lyon AR. Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. *Curr Treat Options Cardiovasc Med.* 2018;20:55. <https://doi.org/10.1007/s11936-018-0641-z>.
31. Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? *Lancet Oncol.* 2017;18:e445-e456. [https://doi.org/10.1016/S1470-2045\(17\)30535-1](https://doi.org/10.1016/S1470-2045(17)30535-1).
32. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. *J Am Heart Assoc.* 2017;6:e006513. <https://doi.org/10.1161/JAHA.117.006513>.
33. Kirwan CC, McCollum CN, McDowell G, Byrne GJ. Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis. *Clin Appl Thromb Hemost.* 2015;21:420-427. <https://doi.org/10.1177/1076029615575071>.
34. Díez J, González A, Kovacic JC. Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar. *J Am Coll Cardiol.* 2020;75:2204-2218. <https://doi.org/10.1016/j.jacc.2020.03.019>
35. Leader CJ, Moharram M, Coffey S, Sammut IA, Wilkins GW, Walker RJ. Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. *PLoS One.* 2019;14:e0220837. <https://doi.org/10.1371/journal.pone.0220837>.
36. Park SJ, Cho SW, Kim SM, Ahn J, Carriere K, Jeong DS, Lee SC, Park SW, Choe YH, Park PW, Oh JK. Assessment of Myocardial Fibrosis Using Multimodality Imaging in Severe Aortic Stenosis: Comparison With Histologic Fibrosis. *JACC Cardiovasc Imaging.* 2019;12:109-119. <https://doi.org/10.1016/j.jcmg.2018.05.028>.
37. Slimani A, Melchior J, de Meester C, Pierard S, Roy C, Amzulescu M, Bouzin C, Maes F, Pasquet A, Pouleur AC, Vancraeynest D, Gerber B, El Khoury G, Vanoverschelde JL. Relative Contribution of Afterload and Interstitial Fibrosis to Myocardial Function in Severe Aortic Stenosis. *JACC Cardiovasc Imaging.* 2020;13:589-600.
<https://doi.org/10.1016/j.jcmg.2019.05.020>.
38. Fabiani I, Scatena C, Mazzanti CM, Conte L, Pugliese NR, Franceschi S, Lessi F, Menicagli M, De Martino A, Pratali S, Bortolotti U, Naccarato AG, La Carrubba S, Di Bello V. Micro-RNA-21 (biomarker) and global longitudinal strain (functional marker) in detection of myocardial fibrotic burden in severe aortic valve stenosis: a pilot study. *J Transl Med.* 2016;14:248. <https://doi.org/10.1186/s12967-016-1011-9>.
39. Cameli M, Mondillo S, Righini FM, Lisi M, Dokollari A, Lindqvist P, Maccherini M, Henein M. Left Ventricular Deformation and Myocardial Fibrosis in Patients With Advanced Heart Failure Requiring Transplantation. *J Card Fail.* 2016;22:901-907. <https://doi.org/10.1016/j.cardfail.2016.02.012>.
40. Ravassa S, López B, Querejeta R, Echegaray K, San José G, Moreno MU, Beaumont FJ, González A, Díez J. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. *J Hypertens.* 2017;35:853-861. <https://doi.org/10.1097/HJH.0000000000001258>.

41. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, A de CJ. Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020;9:e015598. <https://doi.org/10.1161/JAHA.119.015598>.

42. Solomou E, Aznaouridis K, Masoura C, Cutajar I, Toutouzas K, Vlachopoulos C, Tousoulis D. Aortic wall stiffness as a side-effect of anti-cancer medication. Expert Rev Cardiovasc Ther. 2019;17:791-799. <https://doi.org/10.1080/14779072.2019.1691528>.

43. Palaniyappan A. Cyclophosphamide induces premature senescence in normal human fibroblasts by activating MAP kinases. Biogerontology. 2009;10:677-682. <https://doi.org/10.1007/s10522-009-9215-5>.

Figures

Figure 1

Study protocol and relative changes in biomarkers in patients with breast cancer. A, The diagram depicts the study protocol. Patients with breast cancer were studied before chemotherapy, after treatment with epirubicin/cyclophosphamide at 3 months (visit 1) and after treatment with taxanes (with or without anti-HER2 therapy) at 6 months (visit 2). The echocardiograms and biomarkers were evaluated at baseline, at visit 1 and at visit 2. B, Relative changes in biomarker levels with respect to baseline in patients with breast cancer at visit 1 and visit 2. Data are expressed as mean values and 95% confidence interval at visit 1 and visit 2. *P<0.01 vs baseline, **P<0.001

vs baseline, $\dagger P<0.05$ vs visit 1, $\dagger\dagger P<0.001$ vs visit 1 (Linear mixed regression adjusted by baseline biomarker levels, followed by pairwise contrast tests with a Bonferroni's-corrected p value and Benjamini and Hochberg multiple test correction). NT-proBNP, amino-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; sST2, soluble suppression of tumourigenicity-2; VCAM-1, vascular cell adhesion molecule-1; PICP, procollagen type I C-terminal propeptide.

Fig 2

Figure 2

Procollagen type I C-terminal propeptide (PICP) levels and early left ventricular dysfunction in patients with breast cancer. A, PICP circulating levels at baseline and after treatment with epirubicine/cyclophosphamide at 3 months (visit 1) followed by treatment with taxanes (with or without anti-HER2 therapy) at 6 months (visit 2), according to absence or presence of subclinical cardiotoxicity at visit 2. Data are expressed as the predicted mean values (estimated marginal means of visits by group) and 95% confidence interval (CI) at baseline, visit 1 and visit 2 after linear mixed regression analysis with PICP as the dependent variable, and subclinical cardiotoxicity at visit 2, visit, their interaction term, and PICP baseline values as fixed effects. $\ast P<0.001$ vs baseline and visit 1. B. Association of PICP with global longitudinal strain (GLS) (solid black line) and 95% confidence intervals (color shade) along treatment after multivariable linear mixed regression with adjustment for body mass index, cyclophosphamide and epirubicine doses, radiotherapy schedule, hypertension, dyslipemia and DGL levels $\geq$ -17% at baseline, and hematocrit, number of lymphocytes, alkaline phosphatase levels, NT-proBNP, VCAM and hs-TnT. The plot depicts the marginal effect of PICP on DGL when log2-transformed PICP is fit in the basal model.

Fig 3

Figure 3

Circulating procollagen type I C-terminal propeptide (PICP) changes predict subclinical cardiotoxicity in patients with breast cancer. Receiver-operating characteristic curves for PICP (green line), amino-terminal pro-brain natriuretic peptide (NT-proBNP) (blue line) and high sensitivity troponin T (hs-TnT) (red line) changes at visit 2 with respect to baseline levels (A) or levels at visit 1 (B) for determining subclinical cardiotoxicity as defined in the main text.

Fig 4

Figure 4

Procollagen type I C-terminal propeptide (PICP) levels at baseline and 1-year changes in left ventricular ejection fraction (LVEF) in patients with heart failure attributed to anthracycline-based cancer chemotherapy (ACC-HF). Violin plots depict LVEF at baseline and after 12-months follow-up in ACC-HF patients categorized according to tertiles of baseline PICP. Red dots are individual values, horizontal lines indicate medians and boxes indicate interquartile ranges (linear mixed regression adjusted by LVEF basal values followed by pairwise contrast tests with a Bonferroni's-corrected p value).

Fig 5

Figure 5

Cancer chemotherapy agents activate collagen metabolism in human dermal fibroblasts. Dot plots represent the fold change in cell viability and in procollagen type I mRNA expression in human dermal fibroblasts stimulated with or without doxorubicin at 5, 50, 250, 500 and 1000 nM (A,B; n=6-8); cyclophosphamide at 5, 10, 50, 100 and 250 μg/mL (C,D; n=3-8) paclitaxel at 1, 2.5, 5, 10, 25 and 50 μg/mL (E,F; n=8-12); and trastuzumab at 0.01, 0.05, 0.1, 0.5, 1 and 2 μg/mL (G,H; n=4-8). Horizontal lines represent the mean. *P<0.05 vs control (Ctrl) (one-way ANOVA followed by Bonferroni or Tamhane's T2 [if inequality of variances] post hoc tests or Kruskal-Wallis test followed by Mann-Whitney U test with Bonferroni correction if required).

Fig 6

Figure 6

Cancer chemotherapy agents activate collagen metabolism in human cardiac fibroblasts. Dot plots represent fold changes in procollagen type I mRNA expression and in the extracellular procollagen type I C-terminal propeptide (PICP) content in human cardiac fibroblasts stimulated with or without 5, 50 and 250 nM of doxorubicin (A,B, respectively; n=5-9), 10, 50 and 100 μ g/mL of cyclophosphamide (C,D, respectively; n=7) and 0.1, 0.5 and 1 μ g/mL of trastuzumab (E,F, respectively; n=6). Horizontal lines represent the mean (one-way ANOVA followed by Bonferroni or Tamhane's T2 [if inequality of variances] post hoc tests).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [CardiotoxMFSuppl9Dic20.docx](#)